Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)
China · Delayed Price · Currency is CNY 41.06
-0.49 (-1.18%)
Apr 9, 2026, 3:00 PM CST
SHA:600329 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 4,917 | 7,292 | 8,206 | 8,231 | 6,892 |
Other Revenue | - | 14.25 | 16.23 | 17.87 | 15.33 |
| 4,917 | 7,307 | 8,222 | 8,249 | 6,908 | |
Revenue Growth (YoY) | -32.70% | -11.13% | -0.33% | 19.42% | 4.60% |
Cost of Revenue | 1,277 | 3,804 | 4,632 | 4,992 | 4,161 |
Gross Profit | 3,640 | 3,503 | 3,590 | 3,258 | 2,747 |
Selling, General & Admin | 2,417 | 2,459 | 2,508 | 2,347 | 1,930 |
Research & Development | 189.81 | 162.38 | 184.63 | 153.15 | 161.05 |
Other Operating Expenses | 61.88 | 63.44 | 57.28 | 76.69 | 64.12 |
Operating Expenses | 2,669 | 2,729 | 2,769 | 2,586 | 2,160 |
Operating Income | 971.15 | 774.04 | 821.03 | 671.32 | 587.04 |
Interest Expense | - | -40.2 | -35.85 | -10.27 | -2.94 |
Interest & Investment Income | 1,646 | 1,937 | 362.75 | 330.35 | 263.97 |
Currency Exchange Gain (Loss) | - | -1.51 | -1.13 | -2.44 | 0.69 |
Other Non Operating Income (Expenses) | 20.24 | -2.55 | -2.71 | 3.63 | -5.3 |
EBT Excluding Unusual Items | 2,637 | 2,666 | 1,144 | 992.59 | 843.46 |
Impairment of Goodwill | - | -53.61 | -18.78 | -19.57 | - |
Gain (Loss) on Sale of Assets | 2.83 | 0.07 | -0.48 | 0.67 | 10.39 |
Asset Writedown | -152.5 | -60.16 | -24.95 | -0.18 | - |
Other Unusual Items | - | 26.13 | -4.51 | 6.67 | 18.96 |
Pretax Income | 2,487 | 2,579 | 1,095 | 980.19 | 872.81 |
Income Tax Expense | 376.7 | 363.56 | 126.66 | 106.93 | 85.93 |
Earnings From Continuing Operations | 2,111 | 2,215 | 968.71 | 873.26 | 786.88 |
Minority Interest in Earnings | 20.27 | 14.12 | 18 | -11.46 | -17.73 |
Net Income | 2,131 | 2,229 | 986.71 | 861.79 | 769.14 |
Net Income to Common | 2,131 | 2,229 | 986.71 | 861.79 | 769.14 |
Net Income Growth | -4.41% | 125.94% | 14.49% | 12.05% | 16.24% |
Shares Outstanding (Basic) | 769 | 769 | 771 | 769 | 769 |
Shares Outstanding (Diluted) | 769 | 771 | 771 | 776 | 769 |
Shares Change (YoY) | -0.27% | 0.07% | -0.71% | 0.94% | -0.04% |
EPS (Basic) | 2.77 | 2.90 | 1.28 | 1.12 | 1.00 |
EPS (Diluted) | 2.77 | 2.89 | 1.28 | 1.11 | 1.00 |
EPS Growth | -4.15% | 125.78% | 15.32% | 11.00% | 16.28% |
Free Cash Flow | 342.45 | 806.86 | 547.56 | 569.34 | 695.45 |
Free Cash Flow Per Share | 0.45 | 1.05 | 0.71 | 0.73 | 0.90 |
Dividend Per Share | - | 1.280 | 1.280 | 1.120 | 0.500 |
Dividend Growth | - | - | 14.29% | 124.00% | 66.67% |
Gross Margin | 74.02% | 47.94% | 43.66% | 39.49% | 39.77% |
Operating Margin | 19.75% | 10.59% | 9.98% | 8.14% | 8.50% |
Profit Margin | 43.34% | 30.51% | 12.00% | 10.45% | 11.13% |
Free Cash Flow Margin | 6.96% | 11.04% | 6.66% | 6.90% | 10.07% |
EBITDA | 1,084 | 893.19 | 947.65 | 786.15 | 701.29 |
EBITDA Margin | 22.05% | 12.22% | 11.53% | 9.53% | 10.15% |
D&A For EBITDA | 112.92 | 119.15 | 126.62 | 114.83 | 114.25 |
EBIT | 971.15 | 774.04 | 821.03 | 671.32 | 587.04 |
EBIT Margin | 19.75% | 10.59% | 9.98% | 8.14% | 8.50% |
Effective Tax Rate | 15.14% | 14.10% | 11.56% | 10.91% | 9.84% |
Revenue as Reported | - | 7,307 | 8,222 | 8,249 | 6,908 |
Advertising Expenses | - | 445.36 | 437.2 | - | 321.16 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.